- Home
- PLRX vs PHAR Comparison
PLRX vs PHAR Comparison
Compare PLRX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- PHAR
- Stock Information
- Founded
- PLRX 2015
- PHAR 1988
- Country
- PLRX United States
- PHAR Netherlands
- Employees
- PLRX N/A
- PHAR N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- PHAR Health Care
- Exchange
- PLRX Nasdaq
- PHAR Nasdaq
- Market Cap
- PLRX 641.5M
- PHAR 627.5M
- IPO Year
- PLRX 2020
- PHAR N/A
- Fundamental
- Price
- PLRX $12.63
- PHAR $9.38
- Analyst Decision
- PLRX Strong Buy
- PHAR Strong Buy
- Analyst Count
- PLRX 7
- PHAR 3
- Target Price
- PLRX $40.50
- PHAR $27.00
- AVG Volume (30 Days)
- PLRX 562.1K
- PHAR 5.8K
- Earning Date
- PLRX 02-26-2025
- PHAR 03-13-2025
- Dividend Yield
- PLRX N/A
- PHAR N/A
- EPS Growth
- PLRX N/A
- PHAR N/A
- EPS
- PLRX N/A
- PHAR N/A
- Revenue
- PLRX N/A
- PHAR $285,745,000.00
- Revenue This Year
- PLRX N/A
- PHAR $20.08
- Revenue Next Year
- PLRX N/A
- PHAR $9.22
- P/E Ratio
- PLRX N/A
- PHAR N/A
- Revenue Growth
- PLRX N/A
- PHAR 30.64
- 52 Week Low
- PLRX $10.22
- PHAR $6.65
- 52 Week High
- PLRX $18.92
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- PLRX 46.03
- PHAR 49.69
- Support Level
- PLRX $11.02
- PHAR $9.14
- Resistance Level
- PLRX $13.71
- PHAR $10.15
- Average True Range (ATR)
- PLRX 0.79
- PHAR 0.57
- MACD
- PLRX -0.15
- PHAR -0.12
- Stochastic Oscillator
- PLRX 49.77
- PHAR 12.44
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.